The U.S. Food and Drug Administration (FDA) is dealing with the aftermath of what could be one of its most controversial decisions impacting women's health and reproductive rights. A switch to over-the-counter status from prescription-only use for Emergency Contraception had been expected in February. On May 6, 2005, in a move that disregarded the opinion of the doctors and scientists on two advisory boards, the drug Levonorgestrel an emergency contraceptive (EC), sold under the brand name Plan B, was not approved for over-the-counter sale. This went against the advice of a 23 to 4 vote in favor of making the drug more accessible to the women who need it to prevent unintended pregnancies. Director of the Office of Women's Health and the FDA Commissioner have resigned from positions at the FDA in protest. "I can no longer serve as staff when scientific and clinical evidence, fully evaluated and recommended for approval by the professional staff here, has been overruled." said Dr. Susan F. Wood, in announcing her resignation.